Masanobu Kitagawa
Overview
Explore the profile of Masanobu Kitagawa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
142
Citations
1421
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sakano M, Tomita Y, Kanazawa T, Ishibashi S, Ikeda M, Oshita H, et al.
Front Oncol
. 2024 Dec;
14:1459940.
PMID: 39723384
Background: Esophageal cancer, particularly esophageal squamous cell carcinoma (ESCC), is a leading cause of cancer-related death and has a poor prognosis. Despite the advancements in multidisciplinary therapies, resistance to conventional...
2.
Takahara H, Kanazawa T, Oshita H, Tomita Y, Hananoi Y, Ishibashi S, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594843
Primary lung cancer is among the cancers with the poorest prognosis, having the highest mortality rate among men and the second highest among women in Japan. While surgery is the...
3.
Tamura K, Tomita Y, Kanazawa T, Shinohara H, Sakano M, Ishibashi S, et al.
Int J Mol Sci
. 2024 Sep;
25(17).
PMID: 39273151
Gastric cancer is one of the most common cancers worldwide, and new therapeutic strategies are urgently needed. Ferroptosis is an intracellular iron-dependent cell death induced by the accumulation of lipid...
4.
Asakawa A, Yoshimoto R, Kobayashi M, Izumi N, Maejima T, Deguchi T, et al.
Cancers (Basel)
. 2024 Jun;
16(11).
PMID: 38893259
Lung squamous cell carcinoma (LSCC) is refractory to various therapies for non-small cell cancer; therefore, new therapeutic approaches are required to improve the prognosis of LSCC. Although immunotherapies targeting B7...
5.
Kawade G, Kurata M, Matsuki Y, Fukuda S, Onishi I, Kinowaki Y, et al.
Lab Invest
. 2024 Feb;
104(4):102027.
PMID: 38311062
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma. New therapeutic strategies are needed for the treatment of refractory DLBCL. 4-Hydroxy-2-nonenal (4-HNE) is a cytotoxic lipid peroxidation marker,...
6.
Hashimoto J, Oh Y, Yamamoto K, Yoshii T, Fukushima K, Kitagawa M, et al.
Injury
. 2023 Oct;
55(6):111136.
PMID: 37867026
Introduction: Although the diagnostic criteria for atypical femoral fracture (AFF) exclude periprosthetic fractures, reports of periprosthetic femoral fractures with characteristics of AFF are rapidly increasing. In this study, we investigated...
7.
Watabe S, Aruga Y, Kato R, Kawade G, Kubo Y, Tatsuzawa A, et al.
Biomedicines
. 2023 Aug;
11(8).
PMID: 37626774
Accumulation of 4-hydroxynonenal (4-HNE), a marker of lipid peroxidation, has various favorable and unfavorable effects on cancer cells; however, the clinicopathological significance of its accumulation in hepatocellular carcinoma (HCC) and...
8.
Iwaya M, Hayashi Y, Sakai Y, Yoshizawa A, Iwaya Y, Uehara T, et al.
Gastrointest Endosc
. 2023 Jul;
98(6):925-933.e1.
PMID: 37392953
Background And Aims: Gastric cancer (GC) is associated with chronic gastritis. To evaluate the risk, the Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) system was constructed and showed a...
9.
Sugita K, Onishi I, Nakayama R, Ishibashi S, Ikeda M, Inoue M, et al.
Commun Biol
. 2023 Jun;
6(1):582.
PMID: 37264057
Comprehensive screenings to clarify indirect cell-cell interactions, such as those in the tumor microenvironment, especially comprehensive assessments of supporting cells' effects, are challenging. Therefore, in this study, indirect CRISPR screening...
10.
Shinohara H, Kobayashi M, Hayashi K, Nogawa D, Asakawa A, Ohata Y, et al.
Int J Mol Sci
. 2022 Nov;
23(21).
PMID: 36362023
Tumor-associated macrophages (TAMs) and abnormalities in cancer cells affect cancer progression and response to therapy. TAMs are a major component of the tumor microenvironment (TME) in breast cancer, with their...